Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine

Current Opinion in Virology

Volumn 23, Issue , 2017, Pages 88-94

  Medaglini, Donata ^a   Siegrist, Claire Anne ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; DRUG CARRIER; RECOMBINANT VACCINE;

CELLULAR IMMUNITY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE IMMUNOGENICITY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOASSAY; IMMUNOLOGY; METABOLOME; VESICULOVIRUS;

DRUG CARRIERS; EBOLA VACCINES; EBOLAVIRUS; GENE EXPRESSION PROFILING; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOASSAY; METABOLOME; VACCINES, SYNTHETIC; VESICULOVIRUS;

EID: 85018352176     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2017.03.008     Document Type: Review

References (33)

1. 1 Dixon, M.G., Schafer, I.J., Ebola viral disease outbreak—West Africa. MMWR Morb. Mortal. Wkly. Rep. 63 (2014), 548–551.
2. 2 Van Kerkhove, M.D., Bento, A.I., Mills, H.L., Ferguson, N.M., Donnelly, C.A., A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making. Sci. Data, 2, 2015, 150019.
3. 3 Kanapathipillai, R., Henao Restrepo, A.M., Fast, P., Wood, D., Dye, C., Kieny, M.-P., Moorthy, V., Ebola vaccine — an urgent international priority. N. Engl. J. Med. 371 (2014), 2249–2251.
4. 4 Ledgerwood, J.E., DeZure, A.D., Stanley, D.a., Coates, E.E., Novik, L., Enama, M.E., Berkowitz, N.M., Hu, Z., Joshi, G., Ploquin, A., Sitar, S., et al. Chimpanzee adenovirus vector Ebola vaccine — preliminary report. N. Engl. J. Med. 9 (2017), 928–938, 10.1056/NEJMoa1410863.
5. 5 Rampling, T., Ewer, K., Bowyer, G., Wright, D., Imoukhuede, E.B., Payne, R., Hartnell, F., Gibani, M., Bliss, C., Minhinnick, A., et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374 (2015), 1635–1646, 10.1056/NEJMoa1411627.
6. 6 Geisbert, T.W., Bailey, M., Hensley, L., Asiedu, C., Geisbert, J., Stanley, D., Honko, A.N., Johnson, J., Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 85 (2011), 4222–4233.
7. 7 Li, J.-X., Hou, L.-H., Meng, F.-Y., Wu, S.-P., Hu, Y.-M., Liang, Q., Chu, K., Zhang, Z., Xu, J.-J., Tang, R., et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob. Health 5 (2016), 324–334, 10.1016/S2214-109X(16)30367-9.
8. 8 Zhu, F.-C., Wurie, A.H., Hou, L.-H., Liang, Q., Li, Y.-H., Russell, J.B.W., Wu, S.-P., Li, J.-X., Hu, Y.-M., Guo, Q., et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389 (2016), 621–628, 10.1016/s0140-6736(16)32617-4.
9. 9 Ledgerwood, J.E., Costner, P., Desai, N., Holman, L., Enama, M.E., Yamshchikov, G., Mulangu, S., Hu, Z., Andrews, C.A., Sheets, R.A., et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29 (2010), 304–313.
10. 10 Kibuuka, H., Berkowitz, N.M., Millard, M., Enama, M.E., Tindikahwa, A., Sekiziyivu, A.B., Costner, P., Sitar, S., Glover, D., Hu, Z., et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: A phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 385 (2015), 1545–1554.
11. 11 Sarwar, U.N., Costner, P., Enama, M.E., Berkowitz, N., Hu, Z., Hendel, C.S., Sitar, S., Plummer, S., Mulangu, S., Bailer, R.T., et al. Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase i clinical trial. J. Infect. Dis. 211 (2015), 549–557.
12. 12•• Agnandji, S.T., Huttner, A., Zinser, M.E., Njuguna, P., Dahlke, C., Fernandes, J.F., Yerly, S., Dayer, J.J.-A., Kraehling, V., Kasonta, R., et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N. Engl. J. Med. 347 (2015), 1647–1660 Preliminary report of three open-label, dose-escalation phase 1 trials and one randomized, double-blind, controlled phase 1 trial to assess safety and immunogenicity of rVSV-ZEBOV at various doses in 158 healthy adults in Europe and Africa. After a single dose rVSVZEBOV resulted reactogenic but immunogenic and safe.
13. 13•• Regules, J., Beigel, J.H., Paolino, K.M., Voell, J., Castellano, A.R., Hu, Z., Muñoz, P., Moon, J.E., Ruck, R.C., Bennett, J.W., et al. A recombinant vesicular stomatitis virus Ebola vaccine. N. Engl. J. Med. 26 (2017), 330–341 376 Report of two phase 1, placebo-controlled, double-blind, dose-escalation trials of rVSV-ZEBOV in 78 adults showing that the vaccine elicits anti-Ebola antibody responses and transient rVSV viremia.
14. 14•• Huttner, A., Dayer, J., Yerly, S., Combescure, C., Auderset, F., Desmeules, J., Eickmann, M., Finckh, A., The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect. Dis. 15 (2015), 1156–1166 Report on phase 1/2, dose-finding, trial in healthy adults conducted in Switzerland, showing that reducing the dose of rVSV-ZEBOV improves lowered antibody responses and did not prevent vaccine-induced reactogenicity (arthritis, dermatitis, or vasculitis.
15. 7) of rVSV-ZEBOV in ring vaccination in Guinea.
16. 16•• Henao-Restrepo, A.M., Camacho, A., Longini, I.M., Watson, C.H., Edmunds, W.J., Egger, M., Carroll, M.W., Dean, N.E., Diatta, I., Doumbia, M., et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 386 (2016), 857–866, 10.1016/S0140-6736(16)32621-6 Complete report on efficacy and effectiveness of rVSV-ZEBOV in ring vaccination in Guinea.
17. 17 Garbutt, M., Liebscher, R., Wahl-Jensen, V., Jones, S., Möller, P., Wagner, R., Volchkov, V., Klenk, H.-D., Feldmann, H., Ströher, U., Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78 (2004), 5458–5465.
18. 18 Yang, Z.Y., Duckers, H.J., Sullivan, N.J., Sanchez, A., Nabel, E.G., Nabel, G.J., Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6 (2000), 886–889.
19. 19 Jones, S.M., Feldmann, H., Ströher, U., Geisbert, J.B., Fernando, L., Grolla, A., Klenk, H.-D., Sullivan, N.J., Volchkov, V.E., Fritz, E.A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11 (2005), 786–790.
20. 20 Matassov, D., Marzi, A., Latham, T., Xu, R., Ota-Setlik, A., Feldmann, F., Geisbert, J.B., Mire, C.E., Hamm, S., Nowak, B., et al. Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus. J. Infect. Dis. 212 (2015), S443–S451.
21. 21 Mire, C.E., Miller, A.D., Carville, A., Westmoreland, S.V., Geisbert, J.B., Mansfield, K.G., Feldmann, H., Hensley, L.E., Geisbert, T.W., Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl. Trop. Dis., 6, 2012, e1567.
22. 22 Marzi, A., Robertson, S.J., Haddock, E., Feldmann, F., Hanley, P.W., Scott, D.P., Strong, J.E., Kobinger, G., Best, S.M., Feldmann, H., Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349 (2015), 739–742.
23. 23 Geisbert, T.W., Daddario-DiCaprio, K.M., Lewis, M.G., Geisbert, J.B., Grolla, A., Leung, A., Paragas, J., Matthias, L., Smith, M.A., Jones, S.M., et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog., 4, 2008.
24. 24 Marzi, A., Hanley, P.W., Haddock, E., Martellaro, C., Kobinger, G., Feldmann, H., Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in Rhesus macaques infected with Ebola virus Makona. J. Infect. Dis. 214 (2016), S360–S366.
25. 25 Mire, C.E., Geisbert, J.B., Marzi, A., Agans, K.N., Feldmann, H., Geisbert, T.W., Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo Ebolavirus. PLoS Negl. Trop. Dis., 7, 2013.
26. 26 Hagan, T., Nakaya, H.I., Subramaniam, S., Pulendran, B., Systems vaccinology: enabling rational vaccine design with systems biological approaches. Vaccine 33 (2015), 5294–5301.
27. 27 Li, S., Rouphael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt, D.S., Johnson, S.E., Milton, A., Rajam, G., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15 (2014), 195–204.
28. 28 Li, W., Turner, A., Aggarwal, P., Matter, A., Storvick, E., Arnett, D.K., Broeckel, U., Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis. BMC Genom., 16, 2015, 1069.
29. 29• Khurana, S., Fuentes, S., Coyle, E.M., Ravichandran, S., Davey, R.T., Beigel, J.H., Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat. Med. 22 (2016), 1439–1447, 10.1038/nm.4201 Study elucidating the human antibody repertoire after administration of rVSV-ZEBOV and showing a predominat IgM response with a strong virus neutralization activity. A second vaccination did not boost antibody or virus neutralization titers, and induced only minimal antibody affinity maturation.
30. 30 Farooq, F., Beck, K., Paolino, K.M., Phillips, R., Waters, N.C., Regules, J.A., Bergmann-Leitner, E.S., Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. Sci. Rep., 6, 2016, 27944, 10.1038/srep27944.
31. 31•• Huttner, A., et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Sci. Transl. Med., 9, 2017, 10.1126/scitranslmed.aaj1701.
32. 32•• Medaglini, D., Harandi, A.M., Ottenhoff, T.H.M., Siegrist, C.-A., VSV-Ebovac Consortium, Ebola vaccine R&D: filling the knowledge gaps. Sci. Transl. Med., 7, 2015, 317ps24 Description of system biology approach of the VSV-EBOVAC project to decipher the rVSV-ZEBOV vaccine immune signature.
33. 33 Rappuoli, R., Medaglini, D., ADITEC: joining forces for next-generation vaccines. Sci. Transl. Med., 4, 2012 128cm4–128cm4.